MAPT and Alzheimer disease: In the prodromal phase, also described as mild cognitive impairment (MCI) due to AD, first clinical symptoms appear and the levels of amyloid-β peptide (Aβ) and hyperphosphorylated tau (pTau)-mediated neuronal injury increase exponentially.